UNITED
STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE
13D

Under the Securities Exchange Act of 1934

 

 




    
      
      
Sarepta Therapeutics, Inc.
      
    
    
      
      
(Name of Issuer)
      
    
    
      
      
Common
Stock, $0.001 par value per share
      
    
    
      
      
(Title of Class of
Securities)
      
    
    
      
      
803607100
      
    
    
      
      
(CUSIP
Number)
      
    
    
      
      
April 20, 2015
      
    
    
      
      
(Date of Event Which
Requires Filing of this Statement)
      
    





*The
remainder of this cover page shall be filled out for a reporting
person’s initial filing on this form with respect to the subject class
of securities, and for any subsequent amendment containing information
which would alter the disclosures provided in a prior cover page.

The
information required in the remainder of this cover page shall not be
deemed to be “filed” for the purpose of Section 18 of the Securities
Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of
that section of the Act but shall be subject to all other provisions of
the Act (however, see the Notes).




 




    
      
      
(1)
      
      
      
Names of Reporting Persons.
      
      
      
Richard J. Barry
      
    
    
      
      
(2)
      
      
      
Check the Appropriate Box if a Member of a
Group (See Instructions)
      
      
      
(a)    
      ¨
      
(b)    
      ¨
      
    
    
      
      
(3)
      
      
      
SEC Use Only
      
    
    
      
      
(4)
      
      
      
Citizenship or Place of Organization
      
      
      
UNITED STATES
      
    
    
      
      
NUMBER OF
      
SHARES
      
BENEFICIALLY
      
OWNED BY EACH
      
REPORTING
      
PERSON WITH
      
      
      
(5)
      
      
      
Sole Voting Power
      
      
      
3,165,014
      
    
    
      
      
(6)
      
      
      
Shared Voting Power
      
      
      
0
      
    
    
      
      
(7)
      
      
      
Sole Dispositive Power
      
      
      
3,165,014
      
    
    
      
      
(8)
      
      
      
Shared Dispositive Power
      
      
      
0
      
    
    
      
      
(9)
      
      
      
Aggregate Amount Beneficially Owned by Each
Reporting Person
      
      
      
3,165,014
      
    
    
      
      
(10)
      
      
      
Check if the Aggregate
Amount in Row (9) Excludes Certain Shares (See Instructions)
      
      
      
¨
      
    
    
      
      
(11)
      
      
      
Percent of Class Represented by Amount in Row
(9)
      
      
      
7.66%
      
    
    
      
      
(12)
      
      
      
Type of Reporting Person (See Instructions)
      
      
      
IN
      
    
    
      

      
      

      
      

      
      

      
      

      
      

      
      

      
    




 

Item
1.  Security and Issuer:

Common
Stock, $.001 par value per share

Sarepta Therapeutics, Inc.


215 First Street, Suite 7

Cambridge, MA 02142


Item
2(a).  Names of Persons Filing:

Richard J. Barry (“Rick Barry”)


Item
2(a).  Business Address:

c/o Sean Miot, Conifer Securities, LLC

One Ferry Building, Suite 255

San Francisco, CA 94111


Item
2(c).  Present Occupation or Employment:

Private Investor



c/o Sean Miot, Conifer Securities, LLC

One Ferry Building, Suite 255

San Francisco, CA 94111


Item
2(d).  Disciplinary Disclosure Statement (Criminal)

Rick Barry has not been convicted in a criminal proceeding during the last five years.

Item
2(e).  Disciplinary Disclosure Statement (Civil)

Rick Barry has not been a party to a civil proceeding regarding federal or state securities laws during the last five years.

Item
2(f).  Citizenship:

United States

Item
3.  Source and Amount of Funds or Other Consideration:

Rick Barry has been nominated to join the Board of Directors of the Issuer, Sarepta Therapeutics, and has accepted the nomination. No additional purchase or disposition of securities occurred since the last filing of Schedule 13G on February 19, 2015.
Previous purchases have been effected using funds from personal investment accounts.

Item
4.  Purpose of Transaction:

As stated above in Item 3, Rick Barry has been nominated to join the Board of Directors of the Issuer, Sarepta Therapeutics, and has accepted the nomination.

Item
5.  Interest in Securities of the Issuer:

Rick Barry, the sole reporting person of this
Schedule 13D, beneficially owns 3,165,014 common stock shares of the Issuer, 7.66% of the outstanding shares of the Issuer. Mr. Barry maintains sole voting power and sole dispositive power
over all 3,165,014 shares. Since the last filing of Schedule 13G on February 19, 2015, Mr. Barry
has not effected any transactions in this class of securities of the Issuer.

The
calculation of percentage of beneficial ownership in Item 11 of page 2 was derived from the Issuer’s Quarterly Report on Form 10-Q filed
with the Securities and Exchange Commission on November 6, 2014, in
which the Issuer stated that the number of shares of its common stock
outstanding as of October 31, 2014 was 41,309,944 shares.  

Item
6.  Contracts, Arrangements, Understandings or Relationships with Respect to Securities
of the Issuer:

Rick Barry has no contracts, arrangements, understandings
or relationships (legal or otherwise) with respect to any securities of the Issuer.

Item
7.  Material to be Filed as Exhibits

Not Applicable.

Signature

After
reasonable inquiry and to the best of my knowledge and belief, the
undersigned certifies that the information set forth in this statement
is true, complete and correct.




    
      
      
Dated:  May 5, 2015
      
      
      

      
 
      
 
      
By:    /s/ Richard J. Barry
      
Richard J. Barry